Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DR26FMDU3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,553
Award facts
- Contract value 100% obligated
- $42,553.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $42,553.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 tablets of Xtandi 40 mg. This firm fixed-price delivery order, awarded on October 28, 2025, with an ultimate completion date of October 29, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. Xtandi is a branded oncology treatment used in military healthcare systems, and this delivery order represents one of numerous pharmaceutical supply orders DMS Pharmaceutical Group has received from the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, awarded November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As one of multiple regional prime vendor contractors under the $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group supplies a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities worldwide, positioning the company as a critical supplier within the federal military medical pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FMDU3?
SPE2DR26FMDU3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FMDU3 worth?
The government has obligated $42,553 on SPE2DR26FMDU3.
Is contract SPE2DR26FMDU3 an order under another contract?
Yes. SPE2DR26FMDU3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDU3 competed?
The extent of competition for SPE2DR26FMDU3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award